 |
|
|
 |
|
Standard Septic Shock Treatments Ineffective
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 | Next >> The original theory behind using steroid medications to treat septic shock was that doctors hoped it would reduce the inflammation that accompanies septic shock, according to Sprung. However, along with anti-inflammatory action, steroids can also suppress the immune system, which may be detrimental for someone fighting an infection.
Dr. Louis Saravolatz, an infectious disease specialist and chairman of the department of medicine at St. John Hospital and Medical Center in Detroit, also pointed out that it's possible the inflammation seen with septic shock may be part of the body's natural defense, and "maybe it's helping us fight infection."
In any case, the use of corticosteroids in septic shock has remained controversial for decades, and numerous studies have been conducted, often with conflicting results. To try to definitively assess whether or not steroids could provide benefit, Sprung and his colleagues randomly assigned almost 500 people in septic shock to receive either 50 milligrams of hydrocortisone intravenously every six hours for five days, or a placebo. The researchers found no statistically significant differences in survival between the groups. The incidence of septic shock was reversed more quickly in the corticosteroid group, but this benefit was offset by additional episodes of "super-infection" with new sepsis and septic shock.
Text Continues Below

"If it takes 30 years of study [to find a benefit], it probably isn't having a whole lot of effect," Saravolatz noted.
The second study, which was stopped early for safety reasons, sought to compare other commonly used septic shock treatments to assess their efficacy.
German researchers recruited 537 people in septic shock and randomly assigned them to receive either intensive insulin therapy or standard insulin therapy or a modified Ringer's lactate solution versus a pentastarch solution. Pentastarch is a synthetic fluid replacement substance.
Page: << Prev | 1 | 2 | 3 | Next >>
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 1/9/2008
|
 |

SOURCES: Frank Brunkhorst, M.D., senior physician, internal and intensive care medicine, the Clinic for Anesthesiology and Intensive Care, Friedrich Schiller University of Jena, Germany; Charles Sprung, M.D., director, general intensive care unit, department of anesthesiology and critical care medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Louis Saravolatz, M.D., chairman, department of medicine, St. John Hospital and Medical Center, Detroit; Jan. 10, 2008, New England Journal of Medicine
|